Recommencement of OperationsFollowing the successful strategic capital raise in March 2021, the Company has recommenced its corporate and scientific operations. Having been in full hibernation for over 24 months, the opening of operations is being carefully managed as the business is effectively in a “start-up” phase. Recruitment of the scientific team has commenced, and the Company is also seeking new offices as the Parkville site is closing at the end of June 2021. Our chair and executive team including our CFO and CSO are taking on operational and corporate activities required to run the business up to IPO. It is envisaged that a CEO will be identified later this year after the completion of an appropriate recruitment process. Prudent management of resources is ensuring investment into the science program is the first priority. Achievement of the milestones is the major risk and opportunity over the next 12 months. Posted on April 21st, 2021 by Imunexus